AURORA: A New Dawn

Author:

Papanicolaou Genovefa A1,Avery Robin K2,Cordonnier Catherine3,Duarte Rafael F4,Haider Shariq5,Maertens Johan6,Peggs Karl S7,Solano Carlos8,Young Jo-Anne H9,Fournier Martha10ORCID,Murray Rose Ann10,Wu Jingyang10,Bo Tien10,Winston Drew J11

Affiliation:

1. Memorial Sloan Kettering Cancer Center , New York, New York , USA

2. Johns Hopkins University , Baltimore, Maryland , USA

3. Haematology Department, Henri Mondor Hôpital, Assistance Publique-Hopitaux de Paris, and Université Paris-Est-Créteil , Créteil , France

4. Department of Haematology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain

5. Juravinski Hospital and Cancer Center, Hamilton Health Sciences Corporation , Hamilton, Ontario , Canada

6. Haematology Department, University Hospitals Leuven, KU Leuven , Leuven , Belgium

7. Department of Haematology, University College London Hospitals NHS Foundation Trust , London , United Kingdom

8. Hematology Department, Hospital Clínico Universitario, University of Valencia , Valencia , Spain

9. University of Minnesota , Minneapolis, Minnesota , USA

10. Takeda Development Center Americas, Inc , Lexington, Massachusetts , USA

11. Department of Medicine, University of California, Los Angeles Medical Center , Los Angeles, California , USA

Funder

Takeda Development Center Americas, Inc

Publisher

Oxford University Press (OUP)

Reference12 articles.

1. American Society for Transplantation and Cellular Therapy series: #3;Hakki;Transplant Cell Ther,2021

2. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study;Papanicolaou;Clin Infect Dis,2019

3. Maribavir for preemptive treatment of cytomegalovirus reactivation;Maertens;N Engl J Med,2019

4. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir;Papanicolaou;Clin Infect Dis,2023

5. How I prevent viral reactivation in high-risk patients;Dadwal;Blood,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3